CompletedPhase 2NCT05677438

A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia

Studying Alopecia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chong Kun Dang Pharmaceutical
Principal Investigator
ChangHun Huh, MD, PhD.
Seoul National University Bundang Hospital
Intervention
CKD-498 dose#1(drug)
Enrollment
121 enrolled
Eligibility
19-54 years · FEMALE
Timeline
20222023

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05677438 on ClinicalTrials.gov

Other trials for Alopecia

Additional recruiting or active studies for the same condition.

See all trials for Alopecia

← Back to all trials